Results 191 to 200 of about 50,237 (216)

Near-Infrared Organic Structures with Extended Lifetimes to Unlock the Potential of <i>In Vivo</i> Fluorescence Lifetime Imaging. [PDF]

ACS Omega
Chazeau E, Sabea HA, Janssen S, Mateusiak Ł, Van den Dries T, Lapauw T, Sahakian S, Stroet MCM, Dreessen T, Kuijk M, Paul C, Ingelberts H, Hernot S, Romieu A, Goze C, Denat F.   +15 more
europepmc   +1 more source

EphA2/SHP2/SOX8 Axis: A Novel Target for Regulation of Migration and Cetuximab Treatment Sensitivity in Oral Squamous Cell Carcinoma. [PDF]

Mol Carcinog
Yan D, Guo L, Pei F, Zhong K.
europepmc   +1 more source

Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies. [PDF]

Pharmaceuticals (Basel)
Henrykowska G, Bartusik-Aebisher D, Dynarowicz K, Ramesh TS, Smolak B, Aebisher D.   +5 more
europepmc   +1 more source

Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis. [PDF]

Front Immunol
Sun H, Yao Y, Liu X, Qiu R, Chen J, Zhang G, Shu Q.   +6 more
europepmc   +1 more source

Treatment Strategies for Advanced Cutaneous Squamous Cell Carcinoma Following Anti-PD-1 Immunotherapy Failure: A Systematic Review of the Literature and Ongoing Trials. [PDF]

Cancers (Basel)
Thomson H, Adala E, Mandal A, Jones C, Sacco JJ.   +4 more
europepmc   +1 more source

Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study. [PDF]

Signal Transduct Target Ther
Guo Y, Li Z, Xue L, Lin J, Qu S, Sun C, Fang M, Zhu Y, Zong J, Chen W, Cao G, Wu J, Ge M, Li Z, Wang S, Wang X, Jiang H, Hu D, Shen L, Wei Y, Jin C, Zhang H, Huang X, Sun Y, Shi J, Wang M, Luo X, Kuang S, Wei S, Deng R, Shen Y.   +30 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Survival of Patients With Initially Unresectable Colorectal Liver Metastases Treated With FOLFOX/Cetuximab or FOLFIRI/Cetuximab in a Multidisciplinary Concept (CELIM Study)

Annals of Oncology, 2014
Thomas Gruenberger, Wolf Otto Bechstein, Gunnar Folprecht   +2 more
exaly  

Cetuximab, Docetaxel, and Cisplatin as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter, Phase II GORTEC Study

Annals of Oncology, 2015
Joel Guigay, J Fayette, C Sire
exaly  

A Phase II Study of Concurrent Cetuximab–Cisplatin and Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Annals of Oncology, 2012
Stephen Kwok-Wei Chan, Frankie Mo, Ann D King   +2 more
exaly  

KRAS Wild-Type State Predicts Survival and Is Associated to Early Radiological Response in Metastatic Colorectal Cancer Treated With Cetuximab

Annals of Oncology, 2008
Nicola Personeni, Hubert Piessevaux, J -L van Laethem   +2 more
exaly